BioMark Diagnostics Inc. develops liquid biopsy technologies for early cancer detection, with news centered on metabolomic profiling, machine learning models, and lung cancer screening applications. Company updates commonly cover clinical research collaborations, peer-reviewed validation work, respiratory medicine forums, and efforts to apply biomarker testing alongside established screening pathways.
BioMark news also includes intellectual property developments for its metabolic liquid biopsy platform, recognition of collaborative lung cancer screening projects, governance appointments, and commercialization-related activity tied to laboratory standards, distribution channels, and market access for oncology diagnostics.
BioMark Diagnostics (BMKDF) will participate in the MSACL 2026 and BIOHorizon 2026 life sciences conferences in Quebec during the week of October 4, 2026.
At MSACL 2026 in Montreal from October 4–9, the company will join industry workshops with technology partners Sciex and Phytronix Technologies on clinical mass spectrometry workflows. At BIOHorizon 2026 in Laval on October 7–8, Chief Scientific Officer Dr. Jean‑François Haince will speak on a panel about translating biomarker discoveries into clinical practice. BioMark links this dual presence to ongoing expansion of its Quebec City medical laboratory, which is increasing analytical mass spectrometry capacity and advancing laboratory-developed tests toward certification and clinical deployment.
BioMark Diagnostics (OTCQB: BMKDF) reported two new peer-reviewed studies supporting its metabolomics-based liquid biopsy platform for early non-small cell lung cancer (NSCLC) screening and risk stratification, bringing the total to five publications in nine months.
The first study, in Biomedicines, used a 24-feature SEFA model on 800 participants, achieving a test ROC-AUC of 96.9% and 94.4% accuracy. The second, in the International Journal of Molecular Sciences, analyzed 1,038 patients and produced a refined 19‑metabolite panel that maintained high diagnostic accuracy (AUC ≈ 0.91 vs. 0.895) while reducing assay complexity and testing costs. BioMark said these results de-risk its AI/ML-driven platform and support ongoing validation and regulatory efforts in North America.
BioMark Diagnostics (OTCQB: BMKDF) is marking 2026 World Lung Cancer Day by endorsing the global call for equitable access to early lung cancer screening and highlighting its development of a simple, minimally invasive multi-marker liquid biopsy blood test powered by metabolomics and machine learning.
According to BioMark, its platform has been used in Quebec’s provincial lung cancer screening demonstration program and Germany’s HANSE study, providing evidence that metabolomic profiling with algorithms can refine risk assessment, complement existing low-dose CT screening, and help address structural, financial, and geographic access barriers.
BioMark Diagnostics (OTCQB: BMKDF) received formal patent allowances from the Canadian Intellectual Property Office and the European Patent Office for its early-stage lung cancer liquid biopsy.
The minimally invasive blood test targets non-small cell lung cancer, is validated on over 15,000 samples across Quebec, France and Germany, and uses a newly patented algorithm. BioMark is preparing a commercial launch later this year and is prosecuting related patents in the US, China and Japan to support future partnerships and licensing.
BioMark (OTCQB: BMKDF) received a USPTO Notice of Allowance for a U.S. patent application covering a urine-based method of detecting lung cancer using mass spectrometry and metabolomic profiling.
The patent extends BioMark’s liquid biopsy IP from blood to alternative biofluids and covers five clinical uses: detection/diagnosis, staging, population screening, treatment-response assessment, and evaluation of drug efficacy, targeting lung cancer’s 32.1% share of a liquid biopsy market projected above USD $24 billion by 2035.
BioMark Diagnostics (OTCQB: BMKDF) will present its liquid biopsy platform at the Canadian Thoracic Society Research Forum on April 15, 2026 in Calgary as a top-four finalist for the Beaver Den Innovation Award.
The company highlights an AI-enhanced, home-based metabolomics blood test aimed at improving early lung cancer detection and access for rural, northern, and Indigenous populations.
BioMark Diagnostics (OTCQB: BMKDF) announced that a machine learning–driven metabolomics study for lung cancer detection has been accepted for publication in Frontiers in Oncology with notification dated January 15, 2026. The paper, titled "Translational impact of machine learning-driven predictive modeling with pathway-based plasma metabolomic biomarkers for lung cancer detection," describes pathway-level features from the Human Metabolome Database and interpretability using SHAP analysis.
The work was produced in collaboration with Dr. Maria Vaida at Harrisburg University and is expected to be published later this month and made available via the company website. BioMark frames the acceptance as third-party validation of its multi-year AI and machine learning investments in metabolomic profiling.
BioMark (OTCQB: BMKDF) reported major 2025 milestones that advance commercialization of its liquid biopsy platform for early cancer detection. Key 2025 achievements include a 7,000+ patient study completion, selection as exclusive partner for the HANSE 10,000 prospective lung cancer trial, submission of ISO 15189 certification documents in Dec 2025, doubled lab throughput, AI/ML investments, and $4.5M capital raised. Strategic funding includes Horizon Europe support and local grants. Planned 2026 catalysts: ISO accreditation to enable CLIA/CAP and U.S. market entry, HANSE data readouts, publications, licensing deals, launch of ISO-certified laboratory services, and scaling commercial and leadership hires.
BioMark Diagnostics (OTCQB: BMKDF) appointed James Lavender to its board after resolutions at the Annual General Meeting on December 22, 2025. Lavender was a major investor in BioMark's March 2025 financing and is described as supporting the company's transition from development to commercial execution.
BioMark said Lavender brings software development, enterprise sales, and AI/ML expertise, and has helped open high-level channels with state organizations and strategic investors to support the company’s planned U.S. market entry, certification finalization, and lab services expansion.
BioMark Diagnostics (OTCQB: BMKDF) has initiated an ISO 15189 accreditation program with the Standards Council of Canada for its medical laboratory in Quebec City, formally commencing on December 19, 2025.
The company expects an SCC site visit in early 2026 and says ISO 15189 will support its shift from R&D to a commercial-stage diagnostic provider by easing global market access and regulatory pathways. After achieving ISO 15189, BioMark intends to pursue CLIA and CAP accreditations to enable U.S. Laboratory Developed Test services. Management highlighted the accreditation as a quality milestone to reassure hospital procurement teams, biopharma partners, and payors.